Publication details
Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation
| Authors | |
|---|---|
| Year of publication | 2019 |
| Type | Article in Periodical |
| Magazine / Source | American Journal of Hematology |
| MU Faculty or unit | |
| Citation | |
| Web | http://dx.doi.org/10.1002/ajh.25362 |
| Doi | http://dx.doi.org/10.1002/ajh.25362 |
| Keywords | FOLLOW-UP; IMMUNOCHEMOTHERAPY |
| Description | Mantle cell lymphoma (MCL) is still considered to be an incurable subtype of B-NHL, but the outcome is improving and the implementation of anti-CD20 rituximab and high-dose cytarabine (HDAC) into E50 CORRESPONDENCE induction therapy, consolidation with high-dose therapy and autologous stem cell transplant (ASCT), and rituximab maintenance (RM) are currently considered standard approaches for all transplant-eligible patients. Recently, progression free survival (PFS) and overall survival (OS) benefit of RM were confirmed in patients (pts) with MCL treated with R-DHAP and ASCT.1 Whether RM improves outcomes in patients treated with other induction regimens is unknown. As part of the NiHiL observational study in patients with malignant lymphomas (GovTrial No. NCT03199066), we analyzed outcome of 143 consecutive patients with newly diagnosed MCL treated with the Nordic MCL2 protocol followed by ASCT and RM or observation.2,3 The study was approved by the Ethics Committee of the Charles University General Hospital in Prague under number 1816/15S-IV. Further details are described in the Supplemental Methods. |